BioSpace News Archive

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

The CDC is taking a proactive stance and establishing a center that will use forecasting and outbreak analytics to guide public health decision-making.

Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

Lycia will be receiving a $35 million upfront payment from Lilly and is eligible for over $1.6 billion in potential milestone payments.

Noxopharm (ASX:NOX) has reported preclinical data that further supports the role of experimental anti-cancer drug, idronoxil, the active ingredient in Veyonda® , as an anti-inflammatory drug for early-stage COVID-19 treatments.

Global Genes, a leading international rare disease advocacy organization, today announced the launch of a Patient Identification and Engagement for RARE CNS Disorders (PIE4CNS) multi-stakeholder initiative.

NIH Backs Synchron Brain Computer Interface with $10M Grant to Launch First U.S. Clinical Trial

ABVC BioPharma, Inc. today provided an update regarding recent developments in connection with Vitargus®, the world’s first bio-degradable vitreous substitute intended to facilitate retina re-attachment surgery.

SOPHiA GENETICS SA (Nasdaq: SOPH) today announced it will report financial results for the second quarter of 2021 before market open on Thursday, September 9, 2021.

Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the second quarter and six months ended June 30, 2021.